Alexion Pharmaceuticals Inc ALXN:NASDAQ (Common Stock)

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
176.42 8.46   5.04% 1,301,0291.3M
Market data is delayed by at least 20 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Previous close 10/8/2014

Latest News Headlines for Alexion Pharmaceuticals Inc

Alexion Board of Directors Appoints New Chairman and Creates the New Position of Lead Independent Director

CHESHIRE, Conn.--(BUSINESS WIRE)--October 09, 2014-- The Board of Directors of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Leonard Bell, M.D. has been appointed Chairman of the Board of Directors. Dr. Bell, principal founder of Alexion, continues to serve as Chief Executive Officer of the Company. Additionally, R. Douglas Norby has been appointed to the newly created Board position of Lead Independent Director. Mr. Norby, who was voted Lead Independent Director by the other independent members of the Board, has been a Director of Alexion since September 1999. Mr. Norby currently serves as Chair of the Audit Committee, a member of the Nominating and Corporate Governance Committee, and a member of the Risk and Strategy Committee. Both of these appointments follow the passing of Max Link, Ph.D., as announced earlier this week, who served as the Chairman of the Board of Directors of Alexion since December 2002 and as a member of the Board since the Company's inception in 1992.

Alexion Announces the Passing of Max Link, Ph.D., Chairman of the Company's Board of Directors

CHESHIRE, Conn.--(BUSINESS WIRE)--October 07, 2014-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Max Link, Ph.D., Chairman of the Board of Directors of Alexion, passed away unexpectedly on October 5 while traveling on business. Dr. Link, a globally respected leader of companies in the pharmaceutical, biotechnology and medical device industries over the course of nearly four decades, served as a Director of Alexion since the Company was established in April 1992 and assumed the role of Chairman in December 2002. He was 74 years old.

Acquisitions, Senior Level Promotions, Public Offering, and Drug Approvals - Research Reports on Acorda, Alexion, Envision, Lilly and Avanir

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, September 29, 2014 /PRNewswire/ -- Today, Analysts Review released its research reports regarding Acorda Therapeutics, Inc. (NASDAQ: ACOR), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Envision Healthcare Holdings, Inc. (NYSE: EVHC), Eli Lilly and Company (NYSE: LLY) and Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6820-100free.

View more recent headlines

Latest Annual and Quarterly SEC Filings

More Filings
10-K

This report contains detailed information about the company's business finances and management.

10-Q

Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its marketed product Soliris (eculizumab) is the first and only therapeutic approved for patients with two ultra-rare and severe disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria (PNH), an ultra-rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome (aHUS), an ultra-rare and life-threatening genetic disease. On February 7, 2012, it acquired Enobia Pharma Corp. (Enobia). On February 8, 2011, it acquired patents and assets from Orphatec Pharmaceuticals GmbH (Orphatec). On January 28, 2011, it acquired Taligen Therapeutics, Inc. (Taligen). It acquired Asfotase alfa in February 2012.

http://www.alxn.com/

Loading...

collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open167.71
Previous Close176.42
Day High--
Day Low--
52 Week High2/25/2014 | 185.43
52 Week Low10/22/2013 | 100.89
% Off 52 Week High-4.86%
% Off 52 Week Low74.86%
Beta (5 Yr)0.67
Volatility Avg10/8/2014 | 41.50
10-Day Avg. Volume1,307,197
Market data is delayed by at least 20 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)6/30/2014 | 1.99
P/E Ratio6/30/2014 | 88.7
Market CapLarge Cap | 34.9B
Shares Outstanding197.82M
Float196.5M

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield--
Ex-Date--
Dividend Announcement--
Date of Record--
Payable-- - --
Payable Date--

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short3.77M
Short Ratio4.0
Short % of Float1.92%
As of 9/15/2014

Peers Information HelpALXN Alexion Pharmaceuticals Inc vs. Peers

Peers 
ALXN
Alexion Pharmaceuticals Inc
32.76%
Johnson & Johnson
14.54%
Abbott Laboratories
9.94%
Bristol-Myers Squibb Co
-5.53%
Amgen, Inc.
22.78%
ALXN
Alexion Pharmaceuticals Inc
0.00%
Johnson & Johnson
2.67%
Abbott Laboratories
2.09%
Bristol-Myers Squibb Co
2.87%
Amgen, Inc.
1.74%
ALXN
Alexion Pharmaceuticals Inc
5.04%
Johnson & Johnson
2.46%
Abbott Laboratories
1.64%
Bristol-Myers Squibb Co
0.88%
Amgen, Inc.
2.97%
Compare these stocks